Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action

Pharmaceuticals

Bartolomeo Lorenzati¹  Chiara Zucco¹  Sara Miglietta¹  Federico Lamberti¹ 

[1] Department of Internal Medicine, University of Turin, Corso Dogliotti 14, 10126 Turin, Italy;

关键词: hypoglycemic drugs;    sulfonylureas;    thiazolidinediones;    incretin mimetics;   

DOI  :  10.3390/ph3093005

来源: mdpi

【 摘 要 】

Type 2 diabetes is a syndrome characterized by relative insulin deficiency, insulin resistance and increased hepatic glucose output. Medications used to treat the disease are designed to correct one or more of these metabolic abnormalities. Current recommendations of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) include diet and exercise as first-line therapy plus hypoglycemic drugs. Actually there are seven distinct classes of anti-hyperglicemic agents, each of them displaying unique pharmacologic properties. The aim of this review is to describe the pathophysiological basis of their mechanism of action, a necessary step to individualize treatment of diabetic people, taking into proper consideration potential benefits and secondary effects of drugs.

【 授权许可】

CC BY   
© 2010 by the authors; licensee MDPI, Basel, Switzerland.